Barely Significant
← all phrases

“a strong trend”

5,726 sentences · 5,726 papers · 7,352 search hits before verification · confirmed specimen

Sighted at

p=0.077

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

AAV6|a-Syn animals displayed a significantly lower locomotor activity relative to AAV6|GFP (p<0.05) with a strong trend relative to intact Ctrls, indicating a desensitization of dopaminergic striatal receptors or loss of postsynaptic neuronal targets at 6 months with indications of dysregulation already at 8 weeks ( Fig. 1 A–B ).
We observed that the discrimination between control and contaminated rats for this low dose started as a strong trend from 3 months of contamination onward (model 14, Table 2 , panel B; R2Y = 81 %, Q2Y = 58 %) and increased with contamination duration after 6 months (model 15, Table 2 , panel B; R2Y = 82 % and Q2Y = 64 %), and after 9 months (model 16, Table 2 , panel B; R2Y = 84 % and Q2Y = 70 %).
Additionally, patients were stratified based on MGMT promoter methylation and a 9-gene signature; however, they did not identify a group of patients who demonstrated benefit from first-line use of bevacizumab, but patients with MGMT promoter methylation and a favorable 9-gene signature showed a strong trend towards a worse outcome.
In addition, an increase in left hippocampal volume was also associated with an increase in verbal performance of the Buschke selective reminding test.[ 29 ] Based on the CDS, a strong trend for reduced depression was found in a study conducted to determine an increase in the hippocampal plasticity in response to exercise in chronic schizophrenia patients (p. = 0.06).
Indeed, transfer of female offspring ceacal content into young microbiota-depleted female mice for 5 weeks was associated with increased weight of some adipose tissues in GMT Veh-CE-treated mice as opposed to CE-Veh-treated mice, as well as a strong trend to increase glucose-stimulated insulin secretion, which was observed only 4 weeks post-GMT.
to on-pump coronary artery bypass (ONCAB) in the mid/long term as opposed to short-term outcomes.[ 7 ] In the coronary trial which was a randomized controlled trial of ONCAB versus OPCAB with a study population across 16 countries, OPCAB was clearly beneficial in preventing AKIN Stage I AKI-CS with a strong trend toward preventing AKIN Stages 2/3 at 30 days.[ 8 ] However, there was no protection from renal failure requiring dialysis either in the short or intermediate term.[ 8 ] Further, in all prevalence studies of AKI-CS, there is divergence on account of patient enrolment and definitions of the condition, the nature and types of surgery which the individuals underwent.